This literature review discusses the theoretical background of 5a-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, which specifically inhibit the production of dihydrotestosterone by acting as competitive inhibitors of 5a-reductase, are clinically well tolerated and represent an effective treatment option for benign prostatic obstruction. Finasteride is the first compound which has a proven efficacy in chemoprevention of prostate cancer. The aim of this review was to elucidate, if there are sufficient data available to point out clinically relevant differences between the drugs. Both compounds achieve a significant reduction of prostate volume, an improvement of symptoms and a lower risk of acute urinary retention. Whether the different pharmacokinetic and pharmacodynamic properties of Finasteride and Dutasteride are of clinical importance cannot be judged at this time.
Introduction
Data demonstrating the efficacy of the 5ARIs in relieving benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) are mature. 1 This action is achieved through volume reduction of the enlarged prostate, thus reducing the pressure on the proximal urethra and restoring urinary flow. The interest in using 5ARIs in prostate cancer prevention and treatment is related to the suppression of dihydrotestosterone (DHT) formation, a more potent androgen than its precursor testosterone (T) and dates back to 1994. 2 Prostate cancer is the most common malignant tumor in men with microscopic foci of adenocarcinoma in 27% of the prostates in the fourth decade and 34% of the prostates in the fifth decade of life. 3, 4 This high prevalence of microscopic cancer provides a strong argument for chemoprevention. This literature review discusses the theoretical background of 5a-reductase inhibitor (5ARI) treatment and the resulting clinical implications. The differences in the two available compounds, Finasteride and Dutasteride, will be reviewed to determine if a clinically meaningful difference between them exists.
Materials and methods
A Medline-based literature search of peer-reviewed articles addressing 5ARIs, BPH and prostate cancer was performed.
The function of 5a-reductase in the development of BPH T acts as a chemical messenger. It is secreted from the testes following production from adrenal precursors like androstendione. From the extracellular space it diffuses into the prostate along a concentration gradient. Two nuclear membrane-bound steroid 5a-reductase isoenzymes, 5a-R1 and 5a-R2, catalyze the NADPH-dependent reduction of T. 2 The resulting DHT is bound to the androgen receptor within the nuclear membrane of the prostatic epithelial and stromal cells. 5 The DHT-receptor complex dissociates from heat-shock protein (size 80-90k) and becomes transcriptionally active. This dimer binds to androgen response elements on DNA, thus influencing androgen-responsive genes leading, for example, to the production of prostate-specific antigen (PSA) as well as epidermal growth factor and plateletderived growth factor. By these steps prostate cell division and growth is stimulated. 6 Recently it was demonstrated that T (by conversion to DHT) promotes prostate growth by modulating the stromal cell insulinlike growth factor axis and by paracrine action in epithelial cells. 7 Iehle et al. 5 have shown that 5a-R1 and 5a-R2 RNAs occur in all zones of normal prostate as well as in BPH and prostate cancer. In BPH tissue both 5a-R isoenzymes are significantly (Po0.05) more expressed than in the transition zone of the normal prostate. In prostate cancer samples, 5a-R1 was found in a significantly higher concentration as compared to the normal prostate (Po0.05), in contrast to the level of 5a-R2 which was not differentially expressed as compared to the three zones of the normal prostate. This important finding was confirmed in 26 BPH and 53 prostate cancer specimens using immunostaining, which closely correlates to 5a-R activity. The dominant isoenzyme in all samples was 5a-R2, however, 5a-R1 immunostaining was present in BPH stroma in all 26 samples (high in 10 of 26) and BPH epithelium in 25 of 26. The cancer specimen showed 5a-R1 staining in the epithelium in 81% (high intensity in 28%) and in the stroma in 92% (high intensity in 21%). Thomas et al. 8 suggested that 5a-R1 is of greater importance in promoting and maintaining prostate cancer as compared to 5a-R2. In an extension of this work, Thomas et al. 9 found that 5a-R1 moderate plus high intensity immunostaining was augmented from 4.8% of total epithelial area in BPH to 17% in primary over 38% in recurrent, and 55.8% in metastases of prostate cancer, whereas 5a-R2 showed varying responses. Using semiquantitative reverse transcriptase-PCR it was demonstrated, that 5a-R2 is consistently underexpressed in prostate cancer versus normal or hyperplastic prostates. 10 In the absence of androgens, for example prepubertal castration or hypopituitarism, BPH does not occur. In contrast to the circulating levels of T and DHT, which decrease with aging in men, within the prostate DHT predominates and remains high despite falling peripheral T. 6 Supportive evidence may be derived from the familiar incomplete male pseudohermaphroditism due to genetic 5a-R2 deficiency, which prevents BPH formation due to decreased DHT available within the gland.
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This natural condition is recapitulated in 5a-R2 knockout mice which demonstrate a similar phenotype as opposed to type 5a-R1 animals, which are phenotypically normal. 12 Details have been reviewed recently. 13, 14 Selective 5a-R2 inhibition has been shown to decrease serum DHT by about 70.8%, whereas inhibition of both isoenzymes suppressed serum DHT by 94.7%. 15 The corresponding increase of T levels was 13.6 versus 21.2%; LH rose by 0.2 versus 0.3 mIU ml
À1
. 16 After discontinuing treatment with Dutasteride the time to reach undetectable serum levels was 16 weeks; after terminating Finasteride serum DHT climbed to pretreatment levels within 4 weeks. This might have clinical implications in noncompliant patients.
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5ARIs and PSA 5ARIs suppress DHT formation from T thus decreasing the production of PSA. In the Finasteride Long-Term Efficacy and Safety Study (PLESS) the serum PSA levels after treatment with 5 mg Finasteride for up to 4 years fell 57% (median) among men in whose prostate cancer was not diagnosed and 42% among men with prostate cancer. In the placebo arm of the PLESS study PSA rose 10% in BPH patients and 16% in cancer patients. The sensitivity of PSA testing was 66% for an upper limit of normal of 2.0 ng ml À1 on Finasteride versus 70% with placebo. The specificity, however, reached 82 versus 74% for placebo (Po0.001). Thus multiplying PSA by 2 retains its usefulness for prostate cancer detection. 18 In the trials ARIA 3001, 3002 and ARIB 3003, Dutasteride therapy over 12 months lowered total and free PSA by a mean of 45.7 and 55.5%, whereas total PSA levels increased 8.4% and free PSA 14% after 12 months with placebo. The ratio of free to total PSA showed a similar trend, decreasing by a mean of 6.7% on Dutasteride versus increasing by a mean of 6.7% with placebo. After 24 months there was a total PSA decrease of 52.4% with Dutasteride as opposed to an 15.8% increase with placebo. 15 20 In the ARIA 3001 and 3002 trials (n ¼ 2802) the median PSA of patients without a diagnosis of prostate cancer receiving placebo rose from 3.3 ng ml À1 at baseline to 3.5 ng ml À1 after 2 years, that is a median increase of 8.3%. The men on Dutasteride without prostate cancer experienced a PSA decrease from 3.3 to 1.4 ng ml À1 , that is 50.5%. In contrast, those patients with a diagnosis of prostate cancer showed a PSA increase of 23.8%. Using the upper limit of normal for PSA of 4.0 ng ml À1 the sensitivity for Dutasteride versus placebo was 0.671 versus 0.578. Andriole et al. 19 concluded a doubling factor is effective for maintaining the efficacy of PSA for prostate cancer detection. Increases in serum PSA in men treated with Dutasteride should be considered as being suspicious. The optimal balance of sensitivity and specificity was achieved with a PSA increase of 0.8 ng ml À1 from baseline. Marks et al. 21 recommend to use an increase of PSA from nadir of 0.3 ng ml À1 or greater for men receiving Dutasteride as a trigger for biopsy, because of a 71% sensitivity and a 60% specificity for prostate cancer.
The effect of Finasteride and Dutasteride on the clinical progression of BPH
In studying the efficacy of 5ARIs on LUTS and BPH beyond the classical response criteria, PSA predicts and reflects clinical response. The prognostic value of PSA is related to its correlation with prostate volume. To identify men with a total prostate volume of more than 30 ml, as in the ARIA trials, the PSA had to be X1.3 ng ml À1 for men in their fifth decade, X1.5 ng ml
À1
for men in their sixth decade and X1.7 ng ml À1 for men in their seventh decade. 22 The importance of this becomes obvious from the phase-three Dutasteride studies, in which the transition zone volume of the prostate at baseline was measured by transrectal ultrasound. An age-dependent linear relationship between total PSA and total and transition zone volume of the prostate was seen. 23 Baseline PSA allows an assessment of future prostate growth, even surpassing baseline prostate volume, age or other variables. 24, 25 In the placebo arm of the PLESS study after 4 years patients in the lowest PSA tertile (0-1.2 ng ml À1 ) had a volume growth of 7.4%, however, patients in the highest PSA tertile (43.2 ng ml À1 )
5a-Reductase inhibitor treatment J Dörsam and J Altwein demonstrated a 22% growth in prostate volume. 26 In the placebo arm of the phase-three Dutasteride trials, the increase in the transition zone volume was 0.8% in the lowest PSA quartile versus 10.4% in the highest. 27 Thus, the baseline PSA level allows a risk assessment of BPH progression in a given patient, and predicts the response to medical therapy with a 5ARI.
In the PLESS study 1524 men were treated with Finasteride (5 mg) versus 1516 with placebo. Baseline characteristics were among others: PSA 2.8 ± 2.1 (both arms), and prostate volume 55±26 versus 54±25 ml. After 4 years the prostate volume decreased 18% with Finasteride, and increased 14% with placebo, paralleled by a symptom score reduction of À3.3 versus À1.0. The overall risk reduction of BPH-related surgery was 55%, in the lowest PSA tertile it was 35% as opposed to 66% in the highest PSA tertile. Finally, Finasteride lowered the risk of acute urinary retention over placebo by 57%, again 51% in the lowest PSA tertile versus 74% in the highest PSA tertile. 23, 26 From the ARIA trials 4-year data are available as well: these were 2-year, randomized, double-blind, placebocontrolled studies of Dutasteride in the treatment of men with symptomatic BPH, followed by 2-year open-label extension studies. 20 21 .7% in patients after 24 months on placebo plus 24 additional months on Dutasteride. An acute urinary retention occurred after 24 months in 1.9 versus 4.6%, and in 3.3% after 48 months therapy with Dutasteride versus 6.7% after 24 months on placebo and 24 months on Dutasteride. In the lowest quartile of PSA (1.5-2.9 ng ml À1 ), the incidence of acute urinary retention was 1.6%, but 9.0% in the highest (PSA46.0 ng ml À1 ). The same held true for the need of BPH-related surgery with 2.9% in the lowest, but 7.5% in the highest PSA quartile. 23 In the three ARIA trials 1162 men had a baseline T less than 300 ng (100 ml)
, ranging from o150 to 299 ng (100 ml) À1 . Sexual function was impaired in men with T values o225 ng (100 ml) À1 , however, prostate volume or PSA were unrelated. Thus, Dutasteride was effective even in these hypogonadal men. 28 Recently, nomogram-based pertinent baseline parameters, for example symptom scores, Q max and PSA were validated, permitting the prediction of acute urinary retention or eventual surgical intervention. It can be calculated that Dutasteride reduces the risk of these events within 2 years by 50%. 29 In a randomized, double-blind trial 813 patients received 0.5 mg Dutasteride and 817 patients 5 mg Finasteride. The volume reduction was not statistically different; numerically the symptom and flow rate improvement was in favor of Dutasteride. 30 In another comparative study recruiting 240 patients who were treated with Dutasteride (n ¼ 120) or Finasteride (n ¼ 120) over 6 months, 57% under Dutasteride versus 77% under Finasteride had no change in their symptom score, 30% over 18% had a 1 point, 12% over 4% had a 2 point, and 2% over 1% a 3 point improvement.
31 5ARIs combined with a-blocker
In the Medical Therapy of Prostatic Symptoms trial (MTOPS) 3047 men were treated over 4.5 years with placebo, doxazosin (final daily dose 8 mg), Finasteride or their combination. 32 The risk of clinical progression of BPH was significantly lowered by doxazosin (39%) and Finasteride (34%) versus placebo, however, the combination of doxazosin and Finasteride reduced the risk by 66% (Po0.001). The risk of acute urinary retention and BPH-related surgery was significantly reduced only by Finasteride or the combination therapy. The prostate volume in men receiving placebo or doxazosin increased by 24%. The 427 men being exposed to Finasteride and the combination therapy with large volumes had a reduction of 19% (mean 12 ± 30). Pretreatment prostate volume matters if one considers a combination of 5ARIs with an a-blocker. In the MTOPS study, patients with a 25 ml prostate did not benefit from such a combination. However, in prostates measuring 25-40 or 440 ml the combination therapy was superior to either doxazosin or Finasteride alone in preventing progression. 33 Accordingly, in the Symptom Management after Reducing Therapy (SMART-1) study only patients with a total prostate volume X30 ml (n ¼ 327) were included. The patients had been treated with 0.5 mg Dutasteride plus 0.4 mg Tamsulosin daily over a period of 24 weeks; then the patients were randomized to Dutasteride plus placebo or a combination medication. A total of 77% of men after discontinuation of Tamsulosin felt better or not worse compared with week 24. 84% of the patients with an International Prostatic Symptom Score (IPSS) of o20 switched without noticeable deterioration, however, 42.5% of the patients with a baseline IPSS 420 faired worse versus 14% of the patients who stayed on Dutasteride plus Tamsulosin. 34 Obviously, men with severe bladder outlet obstruction should be treated over a longer time period.
In applying the RAND appropriateness method an expert panel of 12 urologists showed a strong positive correlation for 5ARIs in treating the benign prostatic syndrome for IPSS 8-19, total prostate volume 30-59 ml, and even stronger X60 ml, postvoid residual urine, but a weak negative correlation for Q max 10-15 or o10 ml s À1 . The combination therapy showed a very strong positive correlation to the prostate volume and the IPSS, a moderate correlation to the Q max and the residual urine. 35 
Chemoprevention of prostate cancer
The development of chemoprevention drugs is the focus of the AACR Task Force. 36 Genetic mutations and the resulting loss of cellular growth control and apoptosis mechanisms cause progression from normal tissue via prostatic intraepithelial neoplasia grade I-III to manifest prostate cancer. This apparently occurs in a stepwise manner providing a potential target for chemoprevention.
Out of the possible interventions for prevention of prostate cancer, the 5ARI Finasteride was the first compound subject to a population-based phase-three trial, sponsored by the National Cancer Institute, the 5a-Reductase inhibitor treatment J Dörsam and J Altwein prostate cancer prevention trial (PCPT). A total of 18 822 men 455 years of age, a normal digital rectal examination (DRE) and a baseline PSA level o3 ng ml À1 were randomly assigned to Finasteride (5 mg per day) or placebo for 7 years. Prostate biopsy was recommended if the subsequent annual PSA level, adjusted for the Finasteride effect, exceeded 4 ng ml À1 or a DRE was suspicious. The primary end point was the prevalence of prostate cancer during the 7 years of study, diagnosed by 'for cause' biopsies or 'end-of-study' biopsies. In the PCPT the prevalence of prostate cancer was reduced by 24.8% (95% confidence interval 18.6-30.6) from 24.4 to 18.4% in men treated with Finasteride (relative risk 0.75%). The prevalence of cancer with a Gleason sum 7-10, however, was 6.4% in the Finasteride group versus 5.1% in the placebo group (95% confidence interval 1.07-1.50; relative risk 1.27). 37 The latter observation instigated an intensive discussion as to the benefits of Finasteride-based prevention of prostate cancer. One question is whether the increased prevalence of high-grade prostate cancers is real or artifactual. 38 It has been speculated, that lower intraprostatic DHT could account for higher Gleason grades, as this was noticed in hypogonadal men with prostate cancer in comparison to normogonadal men. 39 Another possibility is that Finasteride might selectively inhibit low-grade cancers, whereas high-grade cancers are more resistant to suppressed T levels. 37 This hypothesis is consistent with the observation from the pre-PSA era that high-grade tumors were more resistant to androgen suppression than low-grade tumors. Pathologists have pointed out, that the Gleason grading system has only been validated for prostate glands being hormonenaïve. 40 As Finasteride changes the appearance of prostatic epithelium, the diagnosis of high-grade cancer is less clear. 41 Another potential confounder is the possibility of overdetection bias. The area-under-the-curve in the ROC curve for PSA in the Finasteride arm is larger for Gleason scores 8-10 than in the placebo arms and due to the approximately 25% volume reduction a larger proportion of the gland is biopsied. 38, 42, 43 Furthermore, the difference between Finasteride and placebo can only be seen in the first year of the study, but did not change in the ensuing years. 44 In calculating the absolute benefit/ absolute risk ratio under the assumption of a 25% overdetection bias and 25% high-grade disease being an artefact, the ratio would be impressive 10.9:1. 38 In a recent paper presenting updated results of the PCPT, the authors showed, that patients who underwent prostatectomy had a prevalence of high-grade prostate cancer of 6.0% in the Finasteride and of 8.2% in the placebo arm. There was a risk reduction of 27% even in the high-grade prostate cancer population. Another conclusion is that men interested in cancer prevention should be informed of the opportunity to take Finasteride for preventing prostate cancer. 45 Activity of 5ARIs in prostate cancer Cell line studies. In androgen-responsive human prostate cancer cell lines, for example PC-82 the 5ARI SK&F 105657 can produce antitumor effects through a substantial reduction in tissue DHT. 46 Even androgenunresponsive cell lines, for example DU 145 still posses the 5a-reductase isoforms 5a-R1 and 5a-R2, whereas the cell line PC-3 expresses only 5a-R1. 47 Therefore it has been suggested that T may still be activated in androgenunresponsive cancer cells. Even in cells derived from recurrent prostate tumors, the androgen receptor is still highly expressed and exceptionally sensitive to very low DHT concentrations, and therefore able to enhance the growth of these cells. 48 This suggests that the androgen receptor is transcriptionally active in recurrent prostate cancer, for example in patients with low androgen levels after castration.
Finasteride suppresses the T-induced PSA gene expression in androgen-responsive cells in a dosedependent manner, demonstrating that DHT is the major mediator of androgen drive. 49 To achieve an apoptotic response, that is killing the LNCaP cells, it takes a dual 5ARI like Dutasteride, because both 5a-R isoforms are present and functionally important in LNCaP cells.
In comparing Dutasteride versus Finasteride, again using LNCaP cells, the former 5ARI was more potent in inhibiting the DHT-induced PSA secretions and cell proliferation. In LNCaP xenografts in nude mice, on an equimolar basis, Dutasteride inhibited the growth more strongly than Finasteride. 50 Interestingly, Dutasteride but not Finasteride competed for androgen receptor binding in LNCaP cells resulting in apoptosis. 51 Recently, this was confirmed in androgen-sensitive prostate cancer cell lines-including LNCaP and the androgen receptorexpressing PC-3 (AR2) cell line.
14 The anticancer efficacy of Dutasteride is not equivalent to castration in the LNCaP xenograft model, but the combination of Dutasteride plus castration produced the strongest tumor inhibition (Po0.05). 50 Studies with prostate cancer tissue. The prerequisites for the application of Dutasteride in prostate cancer were studied in tissue obtained through biopsies or sampled from radical prostatectomy specimens after various pretreatment regimes:
The presence of both 5a-reductase isoenzymes in prostate cancer specimen has been repeatedly demonstrated. 5, 52 Expression differences, however, have been observed. Luo et al. 10 found a consistently decreased expression of 5a-R2 in 25 prostate cancer samples; but the 5a-R1 gene was still expressed. The activity of the 5a-R isoenzymes in the prostate cancer tissue varied and was even unmeasurable. Interestingly samples with higher 5a-R1 activity had the highest Gleason scores. High intensity 5a-R1 immunoreactivity was present in 28% of cancer specimens. 51 The same group demonstrated an increased immunostaining for 5a-R1 in primary prostate cancer compared with BPH tissue, whereas 5a-R2 mRNA and immunostaining levels are decreased. Both 5a-R isoforms are increased in 'androgen-independent' cancer which may reflect an adaptive or selective mechanism to amplify any remaining androgen signal. 8 The application of inhibitors of the 5a-R1 and 5a-R2 isoforms in cultures of primary prostate cancer decreased the cell proliferation dose-dependently through auto-or paracrine mechanisms. 53 When patients are treated with Dutasteride 6-10 weeks before radical prostatectomy the intraprostatic DHT 5a-Reductase inhibitor treatment J Dörsam and J Altwein was reduced by 97% and apoptosis was augmented possibly indicating tumor regression. 52 The effect of androgen deprivation on prostate cancer tissue was also investigated. Nishiyama et al. 54 measured serum-and tissue DHT in 103 patients biopsied for suspicion of prostate cancer. A total of 30 patients with localized cancer were treated neoadjuvantly for 6 months with LH-RH-agonists or castration plus flutamide (withdrawal of flutamide due to side effects in 8 patients). Despite androgen deprivation, DHT concentration in cancer tissue remained at approximately 25% of baseline values. The serum DHT was suppressed to 7.5% of pretreatment levels. The serum levels of adrenal androgens were reduced by 60%. In recurrent prostate cancer tissue, even T levels remain similar to androgen-stimulated benign prostates. 55 The DHT concentration in locally recurrent prostate cancer tissue during androgen deprivation decreased by 91%, however, the residual DHT maybe sufficient for androgen receptor activation. The tissue DHT remaining in androgen-deprived tumors is suggestive of intracrine production. 56 These findings were corroborated by Page et al., 57 who demonstrated after shortterm LH-RH-agonist exposure, that intraprostatic T-and DHT levels remained at 20-30% of control values. Titus et al. 58 also demonstrated a shift of expression and isoenzyme activity of 5a-R2 towards 5a-R1 in recurrent prostate cancer. Thus dual inhibition of these isoenzymes might retard the progression of recurrent prostate cancer.
Clinical experience
5ARI monotherapy in the treatment of prostatic carcinoma appeared insufficiently active. There are mainly small-scale studies of 5ARIs in combination with antiandrogens in locally advanced or recurrent prostate cancer. The combination of Finasteride (5 mg per day) plus Flutamide (375-750 mg per day) was given to 22 sexually active men with T3, N0 (n ¼ 6) or N þ (n ¼ 16) prostate cancer. After 24 months, the median PSA was 2.8 ng ml
À1
. Sexual function was maintained in 86% of patients. 59 Barqawi et al. 60 treated 71 men with rising PSA after primary therapy with the same medication and dosage. Of 54 patients available for follow-up, 27 achieved a PSAo0.4 ng ml À1 . Breast tenderness (90%) was the most common side effect. Gleave et al. 61 studied Dutasteride 3.5 or 0.5 mg per day versus no therapy for 4 months before radical prostatectomy. Serum and tissue DHT dropped by X90%. The total prostate and tumor volumes were reduced. Another indication for peripheral androgen blockade is neoadjuvantly before brachytherapy. After 3 months of Bicalutamide (50 mg per day) plus Dutasteride (0.5 mg per day), the prostate volume was reduced in 31 patients by 33.6 and 34.6% using volumetric and ellipsoid volume determinations, respectively. The transition zone dimensions decreased 11.4-19.9%. The extent of volume shrinkage has not been directly compared, but appears comparable to the effect of LH-RH-agonists with or without an antiandrogen. 62 Early prostatic carcinoma is increasingly often managed by an active surveillance strategy without treatment. The favorable safety profile of 5ARIs and their potential to prevent prostate cancer or to delay cancer progression is a strong argument for their use in prostate cancer treatment and warrant further investigation. A placebocontrolled, randomized study has been initiated to examine a potential delay in the progression of low-risk prostate cancer by the use of a 5ARI. 63 The absolute risk-absolute benefit ratio for 5ARIs in the treatment of prostate cancer cannot be determined at this time due to the limited data available.
Conclusions
Dutasteride and Finasteride are well-established drugs in the treatment of LUTS caused by benign outlet obstruction. In the treatment of this condition, there is no clear superiority of one drug over the other. Finasteride is the first drug ever with a proven efficacy in chemoprevention of cancer. Owing to the different distribution of the two isozymes 5a-R1 and 5a-R2 in BPH and cancer tissue, an inhibition of both enzymes seems to be advantageous in cancer patients. At present, it remains unclear if this is of any clinical relevance.
